Implantable Peptide Devices: Long-Acting Delivery Systems

Here is a question that rarely gets asked in peptide therapy: what if the patient did not have to do anything at all?

Not swallow a pill on an empty stomach. Not draw up a syringe. Not press a microneedle patch against their arm. What if a clinician placed a device under the skin during a brief office procedure, and it delivered a steady stream of peptide for three months, six months, or a full year — with zero patient involvement until the next appointment?

That is what implantable peptide devices do. And unlike most needle-free delivery technologies, several of them are already FDA-approved and in clinical use.

This article covers the full range of implantable peptide delivery: from biodegradable polymer depots that have been on the market for decades, to osmotic mini-pumps that nearly reached approval for GLP-1 delivery, to next-generation hydrogel and smart systems in development.

Why Implants? The Adherence Argument

The clinical case for implantable peptide devices rests on a single, well-documented fact: people do not take their medications as prescribed. This is not a character flaw — it is a predictable outcome of asking patients to perform a complex, often uncomfortable task repeatedly over months and years.

For injectable peptides, the adherence data are bleak. Fewer than 50% of chronic diabetic patients adhere to their prescribed insulin regimen. For GLP-1 receptor agonists, one analysis by Intarcia Therapeutics found that poor adherence with pills and injections in type 2 diabetes accounts for a 75% reduction in efficacy between real-world patients and clinical trial participants. Even weekly injectables like semaglutide see one-year persistence rates that often fall below 60%.

Implantable devices bypass adherence entirely. Once the device is in place, the patient cannot forget a dose, skip an injection, or store the medication improperly. The drug releases continuously at a predetermined rate. The only "adherence" required is showing up for the next office visit — something most patients with chronic conditions already do.

For diseases requiring long-term peptide therapy — prostate cancer, central precocious puberty, type 2 diabetes, obesity, endometriosis, growth hormone deficiency — this approach can transform outcomes by eliminating the gap between what a drug can do and what it actually does in practice.

FDA-Approved Peptide Implants

Histrelin Implants: A Year of Continuous Peptide Delivery

Histrelin is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH). Like the naturally occurring hormone, it stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). But continuous administration — rather than the pulsatile release the body normally produces — causes the pituitary to downregulate GnRH receptors, eventually shutting down LH and FSH production and, with them, sex steroid synthesis.

This is the pharmacological basis for treating hormone-dependent conditions: prostate cancer (by reducing testosterone to castrate levels) and central precocious puberty (by suppressing premature sex hormone production).

Supprelin LA is a 50 mg histrelin acetate subcutaneous implant, approved by the FDA in May 2007 for central precocious puberty. It is inserted in the inner aspect of the upper arm during a minor office procedure and delivers approximately 65 micrograms per day for 12 months.

The Phase 3 clinical data were strong:

36 children (33 female, 3 male), ages 4.5-11.6 years
Mean peak stimulated LH levels remained suppressed below the pubertal threshold of 4 mIU/mL throughout 12 months of treatment
31 of 32 eligible patients chose to continue with annual re-implantation in the long-term extension
Within 6 months of implant removal, LH levels returned to pubertal range, confirming full reversibility
Bioavailability from the implant was 92%

Vantas was the prostate cancer version — same 50 mg histrelin acetate implant, delivering approximately 50 micrograms per day for 12 months. In its registration study (n=138), testosterone declined to castrate levels within 2-4 weeks of insertion in virtually all patients. The implant site reaction rate was 13.8%, all mild and mostly associated with the insertion or removal procedure.

Vantas is no longer available (manufacturer Endo cited manufacturing inconsistencies beginning in 2020), leaving Supprelin LA as the only commercially available histrelin implant. At roughly $45,000 per Supprelin LA implant, cost remains a significant barrier — one reason off-label use of the cheaper (but now discontinued) Vantas had become common in some clinical settings.

The histrelin implant demonstrates a key principle: a peptide that would otherwise require daily injection can instead be delivered continuously for a year from a single procedure. The peptide does not pass through the GI tract (avoiding oral degradation challenges), the liver, or the skin. It goes directly from device to subcutaneous tissue to bloodstream.

Leuprolide Depot Formulations: The PLGA Workhorse

Leuprolide acetate (brand names: Lupron Depot, Eligard, Fensolvi, Camcevi) is the most commercially successful example of long-acting peptide delivery. This GnRH analog treats prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. Without a depot formulation, it would require daily subcutaneous injection. With depot technology, dosing drops to once every one, three, four, or six months.

Two distinct polymer technologies make this possible:

Lupron Depot uses PLGA (poly lactic-co-glycolic acid) microspheres. The leuprolide is encapsulated within biodegradable polymer spheres that are injected intramuscularly as a suspension. Over weeks to months, the polymer degrades through hydrolysis, gradually releasing the peptide. The front chamber of the prefilled syringe contains 3.75 mg leuprolide acetate with purified gelatin and PLGA copolymer; the second chamber contains the diluent.

PLGA is a remarkable material for this application. It was already used in children as a resorbable suture material, establishing biocompatibility long before anyone thought to use it for drug delivery. The ratio of lactic acid to glycolic acid in the polymer can be tuned to control degradation rate — and therefore drug release duration. More than 20 PLGA-based products have received FDA approval since 1986.

Eligard takes a different approach: an in-situ-forming implant. Rather than pre-formed microspheres, the product consists of leuprolide dissolved in a biodegradable PLGA polymer dissolved in N-methyl-2-pyrrolidone (NMP) solvent. The two components are mixed immediately before subcutaneous injection. Upon contact with body fluids, the NMP solvent diffuses away, the polymer precipitates, and a solid depot forms at the injection site. The depot then degrades over months, releasing leuprolide at a controlled rate.

Available formulations span a range of durations:

7.5 mg monthly
22.5 mg every 3 months
30 mg every 4 months
45 mg every 6 months

Clinical trials for both Eligard formulations confirmed their ability to suppress testosterone below 50 ng/dL (FDA castration threshold) and below 20 ng/dL (NCCN-recommended threshold for LHRH agonist monotherapy).

The leuprolide depot story matters beyond prostate cancer because it proved the commercial viability of polymer-based long-acting peptide delivery. Every PLGA depot formulation in development today — for peptides, proteins, and small molecules — builds on the manufacturing and regulatory foundations that Lupron Depot and Eligard established.

Other Approved Depot and Implant Systems

Zoladex (goserelin) is a biodegradable PLGA implant injected subcutaneously in the abdomen, releasing the GnRH analog over 1 or 3 months. Like leuprolide, it is used for prostate cancer and endometriosis.

Tesamorelin (Egrifta) is a growth hormone-releasing hormone (GHRH) analog currently administered by daily subcutaneous injection — not yet available in a depot or implant form, but representing the type of peptide therapy that could benefit from long-acting delivery technology.

ITCA 650: The Osmotic Mini-Pump That Nearly Made It

Intarcia Therapeutics' ITCA 650 is the most clinically advanced implantable device designed specifically for metabolic peptide delivery. It is also one of the most instructive cautionary tales about the gap between clinical efficacy and regulatory approval.

The Device

ITCA 650 is a matchstick-sized (approximately 4 mm diameter x 44 mm length) osmotic mini-pump using Intarcia's Medici Drug Delivery System. The engineering is elegant:

A hollow titanium cylinder contains a drug reservoir filled with a concentrated exenatide (GLP-1 receptor agonist) formulation
At one end, a semipermeable membrane separates the device from surrounding tissue
Behind the membrane, an osmotic engine — a chamber filled with high-concentration salt — draws interstitial fluid through the membrane by osmosis
The incoming water increases pressure in the osmotic chamber, pushing a piston forward
The piston displaces exenatide through a micro-orifice at the other end of the device at a constant, zero-order release rate
This process continues until the entire drug reservoir is depleted — 3 to 12 months depending on the formulation

The result: flat, steady plasma exenatide levels with no peaks, troughs, or missed doses. A clinician places the device subdermally during a brief office visit and removes it at the next scheduled visit.

The FREEDOM Clinical Trial Program

ITCA 650's clinical data remain among the most impressive for any non-injectable peptide delivery system:

FREEDOM-1 (Phase 3, double-blind, placebo-controlled, n=460)

Patients: Adults with type 2 diabetes, HbA1c 7.5-10%, on oral antidiabetic drugs
Duration: 39 weeks
HbA1c reduction: -1.1% (40 mcg/day) and -1.2% (60 mcg/day) vs. -0.1% (placebo), p<0.001
Weight loss: -2.3 kg (40 mcg/day) and -3.0 kg (60 mcg/day) vs. -1.0 kg (placebo)
HbA1c <7% achieved by 37% (40 mcg) and 44% (60 mcg) vs. 9% (placebo)
Patients not on sulfonylureas averaged 1.7% HbA1c reduction

FREEDOM-1 HBL (Phase 3, open-label, n=75)

Patients with very high baseline HbA1c (10-12%)
Mean 3.4% HbA1c reduction from a baseline of 10.8%
This is a staggering result — comparable to starting two or three oral diabetes medications simultaneously

FREEDOM-2 (Phase 3, active-controlled, double-blind, double-dummy, n=535)

Comparator: Sitagliptin (Januvia) 100 mg daily — a widely prescribed DPP-4 inhibitor
Duration: 52 weeks
HbA1c reduction: -1.5% (ITCA 650) vs. -0.8% (sitagliptin), p<0.001
Weight loss: -4.0 kg (ITCA 650) vs. -1.3 kg (sitagliptin), p<0.001
ITCA 650 met all primary and secondary endpoints, demonstrating superiority at every measured time point through week 52

FREEDOM-CVO (Phase 3, cardiovascular outcomes trial, n=4,000)

Designed to meet FDA requirements for cardiovascular safety assessment
Placebo-controlled, in patients with established cardiovascular disease or multiple risk factors

Safety across the program: Nausea was the most common adverse event, consistent with the GLP-1 receptor agonist class, and it decreased over time. Discontinuation for GI side effects was in the low single digits over 12 months. The device placement and removal procedures were well tolerated, with minor infection rates at the application site below 1% of all procedures.

Why It Stalled

Despite this clinical evidence, the FDA issued a Complete Response Letter citing manufacturing concerns — not efficacy or safety issues. The agency placed ITCA 650 on clinical hold. Intarcia subsequently resubmitted its NDA, and the FDA accepted it for review. But as of 2026, the device has not received approval.

The manufacturing challenge is real: producing a sealed osmotic pump loaded with a stable peptide formulation, with precise and consistent release rates across millions of units, is a different order of complexity from filling syringes or pressing tablets. Every device must function as both a pharmaceutical product and a medical device, meeting dual regulatory standards.

ITCA 650's story illustrates a recurring theme in implantable drug delivery: the pharmacology often works before the manufacturing does. The peptide stability challenge — keeping exenatide stable at body temperature for 3-12 months inside a sealed device — was solved through proprietary formulation technology. The regulatory and manufacturing challenges proved harder.

Next-Generation Implantable Systems

SUSTAIN Hydrogel Device

A study published in Science Advances evaluated an implantable hydrogel system called SUSTAIN for semaglutide delivery. Comparing subcutaneous injection (which cleared the injection site within 120 hours) to the SUSTAIN device (which retained and released semaglutide over 264 hours — 11 days), the hydrogel more than doubled the delivery window.

While still preclinical, the SUSTAIN approach points toward a class of implantable hydrogels that could be injected as liquid formulations, gel in place at body temperature, and release peptides over weeks — without the engineering complexity of an osmotic pump.

Thermosensitive PLGA-PEG-PLGA Hydrogels

These triblock copolymers exist as liquids at room temperature and form gels at body temperature (37 degrees C). Injected subcutaneously through a standard needle, they solidify in situ to form a drug depot without any surgical procedure. Key advantages:

No organic solvents required in synthesis or purification
No systemic toxicity
Can deliver both hydrophobic and hydrophilic drugs
Biodegradable and biocompatible
Can stabilize peptide and protein drugs within the gel matrix

A 2026 study published in Frontiers in Materials demonstrated a PLGA-PEG-PLGA hydrogel depot for sustained release of mesenchymal stem cell-derived exosomes, promoting wound healing through controlled angiogenesis and anti-inflammatory activity. While not a peptide application directly, the platform is directly applicable to peptide delivery.

In-Situ Forming PLGA Depots

Building on the Eligard concept, newer in-situ forming implants (ISIs) are being developed for additional peptides. One study created an ISI containing 40% PLGA and triacetin that achieved sustained release of 93% of its drug payload over 21 days, with a controllable initial burst effect. This platform is being investigated for glucose-lowering peptides that currently require frequent injection.

Smart Implantable Systems

The frontier of implantable peptide delivery is responsive systems — devices that adjust drug release based on physiological signals:

Magnetically-driven implantable pumps use external magnetic fields to trigger on-demand bolus release of short-acting GLP-1 receptor agonists. The concept: an implanted reservoir with a magnetically actuated valve. The patient (or a wearable controller) triggers a pulse of GLP-1 before meals, combining the zero-adherence benefit of an implant with the prandial dosing pattern of short-acting GLP-1 drugs.

Sequentially triggerable nozzle systems were described in a 2025 Science Advances paper as "ultra-long-lasting" implantable devices capable of on-demand drug delivery for chronotherapy — timed release matching the body's circadian rhythms. These devices could deliver peptide pulses at specific times of day, mimicking the body's natural pharmacokinetic patterns.

3D-printed biodegradable implants are leveraging additive manufacturing to create customized implant geometries with precisely controlled drug release profiles. A 2025 study developed 3D-printed polymer implants for sustained post-surgical drug delivery, demonstrating the feasibility of patient-specific dosing through implant design.

Challenges and Limitations

The Insertion/Removal Procedure

Unlike a patch or a pill, implants require a medical procedure. For subcutaneous implants like Supprelin LA, this means local anesthesia, a small incision, device placement, and wound closure — typically performed in 15-30 minutes in an outpatient setting. The procedure is minor, but it is still a procedure. Patients who are anxious about needles may be equally anxious about incisions.

In-situ forming depots (like Eligard) and injectable microspheres (like Lupron Depot) reduce this barrier by using standard injection technique, but the gauge of needle required is larger than typical injection needles — 18-gauge for some depot formulations compared to 27-31 gauge for standard subcutaneous peptide injection.

Initial Burst Release

Many polymer-based depot systems exhibit a "burst" — a spike of drug release in the first hours or days as drug near the surface of the depot dissolves rapidly before the controlled-release mechanism takes over. For leuprolide and other GnRH analogs, this burst actually causes a transient increase in sex hormones (the "flare" effect) before suppression begins. In prostate cancer, this flare can temporarily worsen symptoms — a clinically meaningful limitation that requires patient counseling and sometimes concomitant anti-androgen therapy.

Newer depot formulations and osmotic pump systems like ITCA 650 are designed to minimize or eliminate burst release, but it remains a challenge for many polymer-based systems.

Peptide Stability at Body Temperature

An implant must keep its peptide payload stable at 37 degrees C for the entire delivery period — months to a year. This is a demanding requirement. Most peptides degrade through hydrolysis, deamidation, oxidation, and aggregation when exposed to physiological temperature and moisture for extended periods. Intarcia's proprietary formulation technology solved this for exenatide in ITCA 650, but each new peptide-device combination requires its own stability solution.

PLGA's degradation products (lactic acid and glycolic acid) create an acidic microenvironment inside the depot, which can destabilize acid-sensitive peptides. Peptide modifications such as PEGylation or cyclization can improve stability, but add complexity and cost to formulation development.

Cost and Access

Supprelin LA costs approximately $45,000 per implant. ITCA 650, had it been approved, would have priced into the GLP-1 market (thousands of dollars per year). The manufacturing complexity of implantable devices — especially precision osmotic pumps — drives costs above those of simple injectable formulations.

For polymer depot products like Lupron Depot and Eligard, the cost-per-dose is more manageable, but still significantly higher than daily generic injections of the same peptide. The economic argument for implants rests on total cost of care: if an implant prevents the consequences of non-adherence (disease progression, hospitalizations, complications), the upfront cost may be justified.

The Road Ahead

The implantable peptide device field in 2026 splits into two tiers:

Established and available: PLGA-based depot formulations (leuprolide, goserelin) and the Supprelin LA histrelin implant represent mature technology with decades of clinical data. These products work, they are reimbursed by insurance, and they are standard of care for their respective indications.

Pipeline and potential: ITCA 650's osmotic mini-pump for metabolic disease, SUSTAIN hydrogel systems, thermosensitive injectable depots for new peptide classes, and smart responsive implants represent the next wave. Each faces its own combination of manufacturing, regulatory, and economic challenges.

The unifying theme is simple: for chronic conditions requiring long-term peptide therapy, removing the patient from the dosing equation produces better outcomes. Every approved implant and depot system confirms this. The question for the next decade is not whether implantable peptide delivery works — the histrelin implant proved that in 2007, and leuprolide depots proved it in the 1980s — but whether the technology can scale to address the massive metabolic disease market where non-adherence extracts the greatest toll.

If ITCA 650 or its successors clear the manufacturing and regulatory hurdles, the impact would be substantial: a GLP-1 receptor agonist that delivers consistent drug levels for six to twelve months, with no injections, no pills, no patches, and no patient effort required beyond visiting their doctor twice a year.

For a field built on the power of peptides, that might be the most powerful delivery technology of all.

This article is part of PeptideJournal.org's Peptide Delivery Technologies cluster. See also: Peptide Delivery Technologies: Beyond the Needle (hub overview), Microneedle Patches for Painless Delivery, and Oral Peptide Formulations.